PACB
Pacific Biosciences of California Inc.
$1.29
+$0.01(+1.18%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$369.46M
Volume
5.96M
52W Range
$0.85 - $2.72
Target Price
$2.05
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $92.8M | $90.7M | $93.5M | $78.6M | $90.9M | $78.9M | $130.5M | $128.3M | $200.5M | $154.0M | ||
| Total Revenue | $37.5M | $64.6M | $93.5M | $78.6M | $90.9M | $78.9M | $130.5M | $128.3M | $200.5M | $154.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-30.7M | $-34.5M | $-58.8M | $-53.5M | $56.3M | $46.3M | $71.7M | $3.7M | $147.7M | $116.7M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $53.5M | $44.2M | $34.7M | $25.1M | $34.6M | $32.6M | $58.9M | $49.0M | $52.8M | $37.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-82.6M | $-115.4M | $-124.4M | $-126.1M | $135.1M | $137.0M | $269.3M | $353.9M | $387.2M | $511.6M | ||
| Research & Development | $60.4M | $67.6M | $65.3M | $62.6M | $59.6M | $64.2M | $112.9M | $193.0M | $187.2M | $134.9M | ||
| Research Expense | $60.4M | $67.6M | $65.3M | $62.6M | $59.6M | $64.2M | $112.9M | $193.0M | $187.2M | $134.9M | ||
| Selling, General & Administrative | $45.2M | $47.8M | $59.1M | $63.5M | $75.5M | $72.8M | $124.1M | $160.9M | $171.8M | $175.0M | ||
| Selling & Marketing Expenses | $45.2M | $47.8M | $59.1M | $63.5M | -- | -- | -- | -- | $2.0M | -- | ||
| General & Administrative Expenses | $-1.1M | $-200.0K | $-6.3M | $-6.2M | $75.5M | $72.8M | $124.1M | $160.9M | $169.8M | $175.0M | ||
| Salaries & Wages | $-13.8M | $-19.6M | $-20.4M | $-23.2M | $16.4M | $300.0K | $900.0K | $78.6M | $600.0K | $9.4M | ||
| Depreciation & Amortization | $-3.7M | $-3.9M | $-8.4M | $-7.2M | $7.3M | $6.4M | $7.2M | $9.5M | $11.5M | $13.8M | ||
| Depreciation & Amortization | $-3.7M | $-3.9M | $-8.4M | $-7.2M | $7.3M | $6.4M | $7.2M | $9.5M | $6.2M | $13.8M | ||
| Amortization | -- | -- | -- | -- | -- | -- | $410.5M | $900.0K | $470.6M | $417.0M | ||
| Other Operating Expenses | $-23.0M | $-115.4M | $-124.4M | $-126.1M | $-1.5M | $-1.2M | $-2.2M | $-2.1M | $-2.1M | $-3.1M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-29.1M | $-71.2M | $-183.3M | $-179.6M | $-100.5M | $-104.4M | $-210.4M | $-307.2M | $-334.5M | $-474.3M | ||
| EBITDA | $-24.1M | $-66.1M | $-79.6M | $-91.9M | $-70.3M | $39.0M | $-250.8M | $-281.5M | $-291.6M | $-256.2M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $2.9M | $3.2M | $2.9M | $2.4M | $2.6M | $267.0K | $12.5M | $15.4M | $14.3M | -- | ||
| Net Non-Operating Interest Income/Expense | $-2.9M | $-3.2M | $-2.9M | $-2.4M | $-2.6M | $-267.0K | $-12.5M | $-15.4M | $-14.3M | -- | ||
| Gain on Sale of Securities | $-344.0K | $-244.0K | -- | -- | -- | -- | -- | $9.2M | $32.8M | $24.9M | ||
| Other Income/Expense | $-364.0K | $-103.0K | $-94.0M | $-79.5M | $-19.0M | $-36.1M | $53.4M | $5.3M | $-15.6M | $-179.0M | ||
| Other Special Charges | $364.0K | $103.0K | $94.0M | $79.5M | $19.0M | $36.1M | $-51.9M | $7.6M | $30.7M | $178.2M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $12.8M | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-184.5M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $184.5M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-28.8M | $-71.1M | $-89.3M | $-100.1M | $-81.5M | $29.7M | $-262.3M | $-298.8M | $-318.2M | $-309.5M | ||
| Pre-Tax Income | $-31.7M | $-74.4M | $-92.2M | $-102.6M | $-84.1M | $29.4M | $-274.9M | $-314.2M | $-318.2M | $-309.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $-113.0M | -- | -- | -- | $-93.6M | -- | $-11.4M | $316.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-31.7M | $-74.4M | $-92.2M | $-102.6M | $-84.1M | $29.4M | $-181.2M | $-314.2M | $-306.7M | $-309.9M | ||
| Net Income (Continuing Operations) | $-31.7M | $-74.4M | $-92.2M | $-102.6M | $-84.1M | $29.4M | $-181.2M | $-314.2M | $-306.7M | $-309.9M | ||
| Net Income (Discontinued Operations) | $-31.7M | $-74.4M | $-92.2M | $-102.6M | $-84.1M | $29.4M | $-181.2M | $-314.2M | $-306.7M | $-309.9M | ||
| Net Income (Common Stockholders) | $-31.7M | $-74.4M | $-92.2M | $-102.6M | $-84.1M | $-68.6M | $-181.2M | $-314.2M | $-306.7M | $-309.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-110.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-113.3M | $-149.9M | $-183.3M | $-179.6M | $191.4M | $183.3M | $340.9M | $357.6M | $535.0M | $628.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $75.6M | $89.1M | $105.7M | $135.1M | $152.5M | $165.2M | $204.1M | $224.6M | $253.6M | $274.5M | ||
| Average Shares Outstanding (Diluted) | $78.3M | $89.6M | $106.0M | $134.9M | -- | $175.0M | $204.1M | $224.6M | $253.6M | $288.4M | ||
| Shares Outstanding | $85.7M | $92.7M | $130.7M | $151.0M | $153.1M | $193.1M | $221.2M | $247.1M | $268.0M | $297.9M | ||
| Basic EPS | -- | -- | -- | -- | $-0.55 | $0.18 | $-0.89 | $-1.4 | $-1.21 | $-1.13 | ||
| Basic EPS (Continuing Operations) | $-0.02 | -- | -- | -- | $-0.55 | $0.18 | $-0.89 | $-1.4 | $-1.21 | $-1.13 | ||
| Diluted EPS | $-0.42 | $-0.83 | $-0.87 | $-0.76 | $-0.55 | $0.17 | $-0.89 | $-1.4 | $-1.21 | $-1.59 | ||
| Diluted EPS (Continuing Operations) | $-0.02 | -- | -- | -- | -- | $0.17 | $-0.89 | $-1.4 | $-1.21 | $-1.59 | ||
| OTHER METRICS | ||||||||||||
| Acquisition Expense | -- | -- | -- | -- | -- | -- | $31.1M | -- | $9.0M | -- | ||
| Commission Expenses | -- | -- | -- | -- | -- | -- | -- | -- | $2.0M | -- | ||
| Development Expense | -- | -- | -- | -- | -- | -- | -- | -- | $2.0M | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | -- | $306.0K | -- | -- | -- | ||
| Net Income From Other Gains Losses | -- | -- | -- | -- | -- | $98.0M | -- | -- | -- | -- | ||
| Other Gand A | $-1.1M | $-200.0K | $-6.3M | $-6.2M | $75.5M | $72.8M | $124.1M | $160.9M | $169.8M | $175.0M | ||
| Other Write Off | -- | -- | -- | -- | -- | -- | $306.0K | -- | -- | -- | ||
| Rent And Landing Fees | $-1.1M | $-200.0K | $-6.3M | $-6.2M | $-7.0M | $-7.2M | $-8.2M | $-11.2M | $-12.1M | $-14.2M | ||
| Selling Expense | $45.2M | $47.8M | $59.1M | $63.5M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | -- | -- | $12.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PACB | $1.29 | +1.2% | 5.96M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Pacific Biosciences of California Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW